Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's a great post and Facts!!!!!
Shorts increase again from 16.7 mill to 18.5 mill Friday
Someone is losing and trying to makeup some ground
If this flys again Monday they will be forced to cover more
Unless this is the company that bashed it all the way down then they made millions and can afford to lose
IMO
News next week!!!
Shorts got burned, went from 5mill to almost 17mill someone is really trying to make some ground up!! But soon will have to cover all
Date Close High Low Volume Short Volume % of Vol Shorted
Mar 23 0.07 0.07 0.039 41,701,579 16,740,626 40.14%
Mar 22 0.044 0.048 0.04 15,542,183 5,193,988 33.42%
Mar 21 0.048 0.051 0.038 33,453,735 12,972,974 38.78%
Mar 20 0.044 0.053 0.033 63,258,964 25,625,561 40.51%
Mar 17 0.031 0.033 0.026 25,909,580 9,291,137 35.86%
Mar 16 0.029 0.03 0.018 36,988,269 11,923,690 32.24%
Mar 15 0.022 0.029 0.02 16,454,388 3,845,122 23.37%
Mar 14 0.027 0.033 0.024 22,768,057 9,114,917 40.03%
Mar 13 0.028 0.035 0.018 49,135,213 11,018,180 22.42%
Mar 10 0.
Only 5mill short
24mill Monday 12mill tues 5mill wed
Def a Nasdaq stock!!!!
Great close
USRM is next!!!!
Nice post from someone on here
Private company
Humacyte Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Expedited Review Designation for HUMACYL® in Vascular Access for Hemodialysis
Posted: Mar 20, 2017 10:02 AM CDT
Updated: Mar 20, 2017 10:02 AM CDT
RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)
Humacyte, an innovator in biotechnology and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted HUMACYL®, its investigational human acellular vessel (HAV), the Regenerative Medicine Advanced Therapy (RMAT) designation. This designation means that the FDA will help facilitate the efficient development and expedited review of the HAV for vascular access to patients in need of life-sustaining hemodialysis. Carved from the model of other FDA expedited programs such as Breakthrough Therapy, the RMAT designation is a new expedited program for regenerative medicine products.
Since receiving the FDA’s Fast Track Designation in 2014, Humacyte has continued to develop clinical evidence indicating that HUMACYL has the potential to address unmet medical needs for hemodialysis patients by decreasing vascular access complications, that in turn may result in more favorable morbidity and mortality outcomes. More than 400,000 people with end-stage renal disease (ESRD) undergo hemodialysis procedures to eliminate deadly toxins from blood when their kidneys fail. Alternative methods are needed to establish durable long-term vascular access for dialysis with infection rates, and other complications as low as possible, to help patients obtain better health care.
Humacyte is currently undertaking a Phase III clinical trial of HUMACYL compared to an expanded polytetrafluoroethylene (ePTFE) graft in 350 patients with kidney failure who are not candidates for fistula placement. The trial involves approximately 35 sites in the U.S., Europe and Israel. The Phase III study’s primary objective is to compare the durable use (secondary patency) of the HAV with that of the ePTFE graft during its use as a conduit for hemodialysis. The company published Phase II results in May 2016, showing HUMACYL may have the potential for long-term use and safety in patients suffering from ESRD who require renal replacement therapy and are not candidates for fistula.
“Being one of the first companies to receive the Regenerative Medicine Advanced Therapy Designation from the FDA is an honor and a testament to the significant potential for HUMACYL to address a great unmet medical need for patients who are undergoing dialysis,” said Carrie S. Cox, Chairman and Chief Executive Officer of Humacyte. “We look forward to continuing to work closely with the FDA to facilitate the development and expedited review of HUMACYL with the goal of bringing this novel vascular access product to patients requiring hemodialysis. We applaud the efforts of the FDA in expanding support to advanced therapeutic products through this great new program.”
Gap up am .045 to .047
We need to run another smear campaign or hit on USRM seems to run it up lol
USRM will set the trend!!! Look at CUR in phase two stem cell
If they deny us this will be awful for all stem companies
Btw CUR is over 5.00
We will set the tone for future approvals then .25% of my earnings will go to CUR lol
And MESO I think is approved for RAT over 8.00
Yes !!!! First to market is a goldmine!!!
Who would want their name all over that, also I think they can extend the patent to recover their investment cost? I may be wrong
Or the shares are their divorce settlement lmao!!!
If the spouse of the chairman willing to risk 24,000 I'd say it makes this a less risk of a bet!!!
Sticky!!!!
Spot on my friend!!!!!!
J&J and USRM are basically in the same field of stem cells
Once FDA approval and USRM 1st to commercialize
J & J will want their name all over it
They bought a company in phase 1
At that time!! Tells you future of medicine
Janssen Inks Up to $337.5M Cell Therapy Collaboration with Capricor
Johnson & Johnson’s Janssen Biotech entered into an exclusive license option agreement to develop Capricor Therapeutics’ cell therapy program for cardiovascular applications—including its lead product, CAP-1002, a heart-disease treatment now heading into Phase II clinical trials—in a deal that could net Capricor as much as $337.5 million.
Janssen agreed to pay Capricor $12.5 million up front, and up to $325 million if Janssen exercises option rights, plus royalties on commercial sales of CAP-1002. Under the agreement, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until 60 days after Capricor delivers six-month follow-up results from Phase II of its ALLSTAR clinical trial for the cell therapy.
CAP-1002 is an allogeneic cardiosphere-derived cell therapy under study in patients who have suffered a large myocardial infarction.
"This collaboration with Janssen, one of the world's largest and most respected healthcare companies with a strong presence in cardiovascular and metabolism, is a tremendous milestone for Capricor Therapeutics and an important validation of our lead product, CAP-1002, and the underlying science,” Capricor CEO Linda Marban, Ph.D., said in a statement.
Capricor has won about $19.8 million in funding from California’s stem-cell agency, the California Institute for Regenerative Medicine (CIRM), toward the Phase II trial, through CIRM’s Disease Team Therapy Development-Research program. The trial will be designed to assess both safety and efficacy of a heart-derived stem cell product in patients who have experienced a heart attack either recently or in the past.
Capricor told CIRM its Phase I data suggest that treatment with the heart-derived cell product under development can turn scar tissue back into healthy heart muscle. The clinical program for CAP-1002 also builds upon earlier research for which Eduardo Marbán, M.D., Ph.D., director of the Cedars-Sinai Heart Institute, won an earlier $5.56 million Disease Team Research I grant from CIRM.
“The planned mid-stage trial will hopefully confirm that finding in a larger patient group and provide additional data to support the safety profile of the product,” the company stated in an abstract of the research published on CIRM’s website.
A successful Phase II trial would be followed by a Phase III study, then a marketing application to the FDA, Capricor added: “The end result could be an affordable stem cell therapy effective as part of a treatment regimen after a heart attack.”
Capricor became publicly traded in July following its merger with Nile Therapeutics, under which Capricor became a wholly owned subsidiary of Nile.
We got this!!! MESO HH pointed out is in phase 3 trading at almost 8.00 a share
.02 is a steal
Do they own any patents? Or all expired?
Yes!!! J&J and USRM are basically in the same field of stem cells
Once FDA approval and USRM 1st to commercialize
J & J will want their name all over it
Janssen Inks Up to $337.5M Cell Therapy Collaboration with Capricor
Johnson & Johnson’s Janssen Biotech entered into an exclusive license option agreement to develop Capricor Therapeutics’ cell therapy program for cardiovascular applications—including its lead product, CAP-1002, a heart-disease treatment now heading into Phase II clinical trials—in a deal that could net Capricor as much as $337.5 million.
Janssen agreed to pay Capricor $12.5 million up front, and up to $325 million if Janssen exercises option rights, plus royalties on commercial sales of CAP-1002. Under the agreement, Janssen has the right to enter into an exclusive license agreement for CAP-1002 at any time until 60 days after Capricor delivers six-month follow-up results from Phase II of its ALLSTAR clinical trial for the cell therapy.
CAP-1002 is an allogeneic cardiosphere-derived cell therapy under study in patients who have suffered a large myocardial infarction.
"This collaboration with Janssen, one of the world's largest and most respected healthcare companies with a strong presence in cardiovascular and metabolism, is a tremendous milestone for Capricor Therapeutics and an important validation of our lead product, CAP-1002, and the underlying science,” Capricor CEO Linda Marban, Ph.D., said in a statement.
Capricor has won about $19.8 million in funding from California’s stem-cell agency, the California Institute for Regenerative Medicine (CIRM), toward the Phase II trial, through CIRM’s Disease Team Therapy Development-Research program. The trial will be designed to assess both safety and efficacy of a heart-derived stem cell product in patients who have experienced a heart attack either recently or in the past.
Capricor told CIRM its Phase I data suggest that treatment with the heart-derived cell product under development can turn scar tissue back into healthy heart muscle. The clinical program for CAP-1002 also builds upon earlier research for which Eduardo Marbán, M.D., Ph.D., director of the Cedars-Sinai Heart Institute, won an earlier $5.56 million Disease Team Research I grant from CIRM.
“The planned mid-stage trial will hopefully confirm that finding in a larger patient group and provide additional data to support the safety profile of the product,” the company stated in an abstract of the research published on CIRM’s website.
A successful Phase II trial would be followed by a Phase III study, then a marketing application to the FDA, Capricor added: “The end result could be an affordable stem cell therapy effective as part of a treatment regimen after a heart attack.”
Capricor became publicly traded in July following its merger with Nile Therapeutics, under which Capricor became a wholly owned subsidiary of Nile.
Great article I wonder what phase J&j are in now? I bet they want USRM
Great article!!! CNN.com very reliable
Don't forget 8.50 buyout on OCAT
We have a larger target audience
Ocata Therapeutics (OCAT) to be Acquired by Astellas in $379M Deal
November 10, 2015 7:10 AM
Astellas Pharma Inc. and Ocata Therapeutics, Inc. (NASDAQ: OCAT) announced today that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a wholly-owned subsidiary of Astellas US Holding, Inc. ("Laurel"). The boards of directors of both Astellas and Ocata have unanimously approved the agreement.
Pursuant to the agreement, Laurel will commence a tender offer for all outstanding shares of common stock of Ocata, for a price of US$8.50 per share in cash (the "Tender Offer"). Promptly upon successful completion of the Tender Offer, Laurel will be merged into Ocata, and any remaining shares of common stock of Ocata will be canceled and converted into the right to receive the offer price (except for shares held by stockholders who properly demand appraisal rights under Delaware law). The board of directors of Ocata has resolved to recommend that Ocata's stockholders tender into the Tender Offer.
Each of the directors and executive officers of Ocata entered into support agreements with Astellas and Laurel, pursuant to which such directors and officers, among other things, agreed to tender the shares of common stock of Ocata that they hold into the Tender Offer. Shares held by these directors and officers represent, in the aggregate, approximately 1.7% of the share of common stock of Ocata outstanding on this date.
The acquisition of Ocata represents the coming together of two companies with significant accomplishments and a shared commitment to development innovative therapies that address the unmet medical needs of patients suffering from severe ophthalmic diseases. The acquisition also represents a step toward achieving Astellas' Strategic Plan 2015-2017.
Further, acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in cell therapy.
"We highly value Ocata's R&D capabilities, including its world-leading researchers in cell therapy," commented Yoshihiko Hatanaka, President and CEO, Astellas. "We're confident that we will turn innovative science into value for patients through the creation of new value by combining both companies' capabilities under 'One Astellas,' where Ocata will be taking a key role in Astellas' R&D in ophthalmology and cell therapy."
Paul Wotton, Ph.D., President and CEO, Ocata said, "I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients suffering from debilitating diseases like AMD and SMD will soon benefit from having access to regenerative medicine."
Financial Details and Closing Conditions
Consummation of the transaction is subject to customary closing conditions, including antitrust approvals and the tender of a majority of Ocata's shares of common stock on a fully diluted basis. The offer price represents a premium of 79% to Ocata's closing share price of US$4.75 on November 6, 2015. The all-cash transaction is valued at approximately US$379 million including the purchase of all common shares, options, warrants and other securities. The Tender Offer period is expected to commence no later than November 25, 2015, and will expire 20 business days after its commencement, unless otherwise extended. If the Tender Offer conditions are not satisfied, Astellas may be required to extend the Tender Offer under certain circumstances; however, in no event will Astellas be obligated to extend the Tender Offer beyond May 9, 2016.
The Tender Offer and consummation of the acquisition is expected to have a minor impact on Astellas' financial results for the fiscal year ending March 31, 2016.
Citigroup Inc. is acting as exclusive financial advisor to Astellas and Covington & Burling LLP is acting as legal counsel.
Jefferies LLC is acting as exclusive financial advisor to Ocata and Goodwin Procter LLP is acting as legal counsel.
by Taboola Sponsored Links You May Like
What Made Joy Behar Sit Slient For An Hour
Lighting Bug Mag News
When You're Ready - Search for Texas Rehab Services
MedicGuru - Search
Casinos Don't Expect You To Do This; But They Can't Stop You
Casino Crusher - Buzz News
29 Crazy Photos That'll Turn You Into a Yoga Fanatic
Journalistate
How Car Dealers Get Rid of Unsold Inventory
Auto Deals Ace
3 Sneaky Tricks To Make Any Woman Obsess Over You...
Girlfriend Activation System
Save money. Live better.™
$63.48 - walmart.com
Search For The Best New Dodge Truck
adviceandhowto.com
Prediabetes: How To Ward Off A Future Diabetes Diagnosis
Mr. Healthy
From The Web
What Made Joy Behar Sit Slient For An Hour (Lighting Bug Mag News)
When You're Ready - Search for Texas Rehab Services (MedicGuru - Search)
Casinos Don't Expect You To Do This; But They Can't Stop You (Casino Crusher - Buzz News)
29 Crazy Photos That'll Turn You Into a Yoga Fanatic (Journalistate)
Real Rarity: Mother Gave Birth to Quadruplets, and Then the Doctor Looked at the … (The Buzz Tube)
Dermira (DERM) Announces CIMZIA Phase 3 Met co-Primary Efficacy Endpoints in Certain Plaqu…
Six Waterford Seniors Named 2017 National Merit Finalists
Form 4 CAVIUM, INC. For: Feb 10 Filed by: Hussain Muhammad Raghib
Eminence Capital's 13F Shows New Stakes in TripAdvisor (TRIP), Imperva (IMPV), Cornerston…
StreetInsider.com - Press Releases
by Taboola Promoted Links
Categories
Corporate News
Hot Corp. News
Hot M&A
Management Comments
Mergers and Acquisitions
Next Articles
Astellas to Acquire Ocata Therapeutics
November 9, 2015 10:05 PM
Wrong!!! Ocat was using stem cells in the eyes / they got bought out for 8.50 a share 349mill
This is a larger target audience
I'm in this just need help with the math from my buddy
I just can't make the math work on 10 billion shares.
50,000 Barrels per day
$5 profit per barrel
365 days per year
$91,250,000 Annual Profit
10,000,000,000 # shares
$0.01 Profit per share
15 PE Ratio
$0.14 share price at stated PE
$1,368,750,000 Market Cap
Never seen a Stem cell company up for FDA - so cheap!!!
This is a gift to all
Retirement stock
Future of medicine
There she blows!!!! Go baby go!!!
Hit up my message box
No significant news next week or the next
Mark this post
Go BIEL!!! Takes time be patient
And let things fall in to place with brand partner and retail stores
We will see green soon enough
Exactly what i thought!! Makes no sense, if they are getting FDA approved or think there is a chance, or buyout then those transactions are pointless
Yes? Why sell your equipment for collateral and 3 year payment plan if they knew this was approved? Or they don't yet and the funds are use to pay them for services such as a buyout
Enlighten me
What was that last trade? Trade?
181k
Was that last trade real? 181k buy
Could this be a ploy to drive shareholders out? If possible buyout then less shares to pay on??
Wtf is happening lol
My buy day is tomorrow / funds hit
Was only going to risk 1k my 1k lottery ticket
I cant buy till funds hit Friday, you longs have put up the good fight
Any chance I can still get in before announced? They have 60 days from Jan?
Regardless of FDA decision this stock is so undervalued considering the future of medicine
What scares me the most is all the reverse splits
I'm a huge believer in what they are doing for the world,.... could this be the year? Or in a few months?
Any idea on when they will release results?
Don't expect anything to happen for at least 3-4 months
It's takes time to set up meetings
Remember this is a product of the future most companies are not educated enough on the technology
If not like Walmart or target will be beating down their door, we have to go after them and beat down their door and educate them on the huge upside to using actipatch and the benefits
.003 open once news hits that's what everyone is waiting on, a sense of direction. Well brand partners are lined up. But Andy wants to hit a homerun I feel Walmart and target is a possibility direct = better margins than using a partner. Be patient
I think .0017 is the low 1000s of $$$ stacked up at .0017 , don't give away ur shares
Anyone know number of shorts left?